Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility21 Feb 2008
Major Shareholder Announcement5 Feb 2008
Major Shareholder Announcement4 Feb 2008
Genmab's Financial Calendar for 200831 Jan 2008
Major Shareholder Announcement30 Jan 2008
Genmab to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference29 Jan 2008
Genmab Reaches Milestones in Ofatumumab Collaboration21 Jan 2008
Genmab Announces HuMax-CD32b Pre-Clinical Program
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
4 Jan 2008
Articles of Association of Genmab A/S dated December 13, 20074 Jan 2008
Genmab to Present at the 26th Annual JPMorgan Healthcare Conference3 Jan 2008
R1507 Antibody to Enter Phase II Study to Treat Sarcoma20 Dec 2007
Genmab Announces Update on Ofatumumab Program14 Dec 2007
  • Previous
  • 1
  • More pages
  • 114
  • 115
  • 116
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863